Acadia Pharmaceuticals Announces New Clinical Data and Pipeline Updates at 2025 International Congress of Parkinson’s Disease and Movement Disorders
Reuters
Oct 02
Acadia Pharmaceuticals Announces New Clinical Data and Pipeline Updates at 2025 International Congress of Parkinson's Disease and Movement Disorders
Acadia Pharmaceuticals Inc. has announced upcoming presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders, scheduled for October 5-9 in Honolulu, Hawaii. The company will deliver a late-breaker oral platform presentation detailing the mechanism of action, preclinical efficacy, and safety evaluation of its investigational drug ACP-711, currently being developed for essential tremor. Additionally, Acadia will present two poster sessions: one outlining the design of a Phase 2, double-blind, placebo-controlled, multicenter study assessing the efficacy and safety of ACP-204 in adults with Lewy body dementia psychosis, and another reporting findings from a post-hoc analysis on the duration of illness and response to NUPLAZID® (pimavanserin) in patients with Parkinson's disease psychosis. The results and study designs will be presented during the congress and have not yet been publicly disclosed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251002463817) on October 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.